CEL-SCI To Participate in Ascendiant’s Quarterly Management Discussion Series Today, Friday February 20 at 11 Am Eastern Time

VIENNA, Va.--()--CEL-SCI Corporation (NYSE MKT:CVM), a late stage cancer immunotherapy company, announced that Geert Kersten, Chief Executive Officer, will participate in Ascendiant’s Quarterly Management Discussion Series teleconference today, Friday, February 20, 2015, at 11 AM ET.

Interested parties may access the call by dialing +1-719-457-6209 and entering passcode 216781. A replay webcast link will be available on the investor relations section of www.cel-sci.com shortly after the call concludes.

About CEL-SCI Corporation

CEL-SCI’s work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. CEL-SCI believes that the best way may be to activate the immune system of patients before they have received surgery, radiation and/or chemotherapy. Its lead investigational immunotherapy Multikine (Leukocyte Interleukin, Injection) is currently being studied in a pivotal Phase III clinical trial against head and neck cancer. If the study endpoint, which is a 10% improvement in overall survival of the subjects treated with Multikine treatment regimen as compared to subjects treated with current standard of care only is satisfied, the study results will be used to support applications which will be submitted to regulatory agencies in order to receive from these agencies commercial marketing approvals for Multikine in major markets around the world. Additional clinical indications for Multikine which are being investigated include cervical dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in HIV/HPV co-infected men and women. A Phase I trial of the former indication has been completed at the University of Maryland. The latter indication is now in a Phase I trial in conjunction with the U.S. Navy under a CRADA (Cooperative Research and Development Agreement).

CEL-SCI is also developing its LEAPS technology for the treatment of pandemic influenza and as a potential therapeutic vaccine against rheumatoid arthritis. The Company has recently received a Phase I SBIR Grant from the National Institutes of Health to develop LEAPS as a potential treatment for RA with researchers from Rush University Medical Center in Chicago, Illinois. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

For more information, please visit www.cel-sci.com.

Contacts

CEL-SCI Corporation
Gavin de Windt, 703-506-9460

Contacts

CEL-SCI Corporation
Gavin de Windt, 703-506-9460